NATIONAL FILARIASIS

ELIMINATION PROGRAM
Presented by RLE GROUP IV-B:
June Stella Marie F. Alli Trixia S. Maduramente
Divine Mercy Bernabe Gina F. Peniero
Sammy Boy D. Deleña Ayka P. Soliman
Loren Fideleanne B. Fuentes Flavia S. Zaldivar
Cassey Grace M. Labong
 Causative agents:
1. Wucheria Bancrofti
2. Brugia malayi
3. Brugia timori
Mode of transmission:
Mosquito bites
 Vector:
Aedes Poecilius
 Incubation Period:

8 to 16 months
Three stages of Filariasis:
A. Asymptomatic Stage
B. Acute Stage
C. Chronic Stage
 Asymptomatic Stage

1. Characterized by the presence of microfilia in

the peripheral blood
2. No clinical signs and symptoms of the
disease
 Acute Stage

1. Lymphadenitis
2. Lymphangitis
3. Feniculitis, epidydimitis, or orchitis
 Chronic Stage
1. Develop 10 to 15 years from the onset of the
attack
2. Hydrocele
3. Lymphedema or Elephantiasis
4. Chyluria
 NATIONAL FILARIASIS
ELIMINATION PROGRAM
Vision, Mission, Goal, General Objective, Specific Objectives, Program
Strategies, and Management
VISION: Healthy and productive individuals and
families for Filariasis-free Philippines

MISSION: Elimination for Filariasis as a public health

problem through a comprehensive approach and
universal access to quality health services
GOAL: To eliminate Lymphatic Filariasis as a public
health problem in Philippines by year 2017

GENERAL OBJECTIVE: To decrease Prevalence Rate of

Filariasis in endemic municipalitites to <1/1000
population
 SPECIFIC OBJECTIVES

a. Reduce the prevalence rate to

elimination level of <1%

b. Perform mass treatment in all

estrablished endemic areas
 SPECIFIC OBJECTIVES

c. Develop a filariasis disability prevention

program in established endemic areas

d. Continue surveillance of established

endemic areas 5 years after mass
treatment
PROGRAM STRATEGIES
a. Endemic mapping
b. Capacity building
c. Mass treatment
d. Support control
 PROGRAM STRATEGIES
e. Monitoring and Supervision
f. Evaluation
g. National Certification
h. International Certification
 MANAGEMENT

a. Selective treatment – treating individuals found to

be positive for microfiliae in nocturnal blood
examination

i. Drug: Diethylcarbamazine Citrate

ii. Dosage: 6mg/kg body weight in 3 divided doses
for 12 consecutive days (usually given after
meals)
 MANAGEMENT
b. Mass Treatment – giving drugs to all population from
aged 12 years and above in all established endemic
areas

i. Drug: Diethylcarbamazine Citrate (single dose

based on 6mg/kg body weight) plus Albendazole
400mg given single dose once annually to people 12
years and above living in established in endemic
areas
 MANAGEMENT

c. Disability Prevention – though home-based or

community based care for lymphedema and
elephanthiasis cases. Surgical management for
hydrocele patientes